| __timestamp | Pfizer Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14097000000 | 10811000 |
| Thursday, January 1, 2015 | 14809000000 | 33001000 |
| Friday, January 1, 2016 | 14837000000 | 64936000 |
| Sunday, January 1, 2017 | 14784000000 | 99909000 |
| Monday, January 1, 2018 | 14455000000 | 127724000 |
| Tuesday, January 1, 2019 | 14350000000 | 161524000 |
| Wednesday, January 1, 2020 | 11615000000 | 182933000 |
| Friday, January 1, 2021 | 12703000000 | 219982000 |
| Saturday, January 1, 2022 | 13677000000 | 278139000 |
| Sunday, January 1, 2023 | 14771000000 | 309799000 |
| Monday, January 1, 2024 | 14730000000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Pfizer Inc. and Ultragenyx Pharmaceutical Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Pfizer, a titan in the industry, consistently maintained SG&A expenses around $14 billion annually, with a slight dip in 2020. This reflects a stable operational strategy, even amidst global challenges. In contrast, Ultragenyx, a burgeoning biotech firm, exhibited a dynamic growth trajectory. From a modest $10 million in 2014, their SG&A expenses surged to over $300 million by 2023, marking a staggering 2,800% increase. This rapid escalation underscores Ultragenyx's aggressive expansion and investment in innovation. As the pharmaceutical sector continues to evolve, these financial strategies offer a glimpse into the diverse paths companies take to achieve growth and sustainability.
Pfizer Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and Dynavax Technologies Corporation
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared